SR One
About SR One
SR One is a biotechnology venture capital firm that partners with founders and entrepreneurs to translate innovative science into medicines. The firm emphasizes a back-and-build approach, focusing on companies with strong fundamentals, clear development pathways, and novel approaches to addressing diseases. With a transatlantic presence, SR One provides geographic reach and regional expertise from its teams in the West Coast, USA and London, UK to support portfolio companies and advance opportunities across geographies.
Recent News
Addition Therapeutics Inks $100 Million Funding
Addition Therapeutics Shows Durable Gene‑Editing Proof‑of‑Concept at ASGCT
Avalyn Pharma Takes a Breath to Raise $300M in IPO Cash for Lung Drug Trials
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement
Corxel Draws $287M Round to Drive Global Development of Oral GLP-1
StockWatch: IPO Market Shows Sign of Life with Avalyn Filing
Odyssey’s IPO Brings In $304M for Quest to Develop Better Immunology Drugs
Recent Deals
Corxel Secures $287M Series D1 Funding to Advance Oral GLP-1 Obesity Pill
Mission Therapeutics Raises $13.3M From Existing Strategic Investors
Addition Therapeutics Secures $100M Funding to Advance Genomic Medicine
Immutrin Secures $87M Series A to Advance ATTR‑CM Antibody Therapy